Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 3/20 | 0.38 |
| ▸ | MME | P08473 | 2/20 | 0.38 |
| ▸ | CPA1 | P15085 | 2/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HRH1 | P35367 | 2/20 | 0.32 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL587179 | 1.00 | ALDH1A1 (0.39) | ALDH1A1ACEMMECPA1ACE2 | |
| SCHEMBL587180 | 1.00 | ALDH1A1 (0.39) | ALDH1A1ACEMMECPA1ACE2 | |
| SCHEMBL31295617 | 1.00 | ALDH1A1 (0.39) | ALDH1A1ACEMMECPA1ACE2 | |
| SCHEMBL26910411 | 0.82 | ALDH1A1 (0.37) | ALDH1A1ACEMMECPA1ACE2 | |
| SCHEMBL196729 | 0.81 | ALDH1A1 (0.39) | ALDH1A1ACEMMECPA1ACE2 | |
| SCHEMBL3149648 | 0.81 | ALDH1A1 (0.39) | ALDH1A1ACEMMECPA1ACE2 | |
| SCHEMBL14889910 | 0.81 | ALDH1A1 (0.39) | ALDH1A1ACEMMECPA1ACE2 | |
| SCHEMBL196730 | 0.81 | ALDH1A1 (0.39) | ALDH1A1ACEMMECPA1ACE2 | |
| SCHEMBL3527314 | 0.81 | ALDH1A1 (0.39) | ALDH1A1ACEMMECPA1ACE2 | |
| SCHEMBL23174419 | 0.79 | HTR2A (0.41) | ALDH1A1ACEMMECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | claimed |
| CN-1303991-C | Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivative process for preparing the same | WARNER LAMBERT CO (US) | 2007-03-14 | — | — | CN | claimed |
| EP-1077692-B1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2004-07-28 | — | — | EP | claimed |
| CN-1301155-A | Stable pharmaceutical formulation of gamma-aminobutyric acid derivatives and process for preparing the same | WARNER LAMBERT CO (US) | 2001-06-27 | — | — | CN | claimed |
| EP-1077692-A1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | Warner-Lambert Company LLC (US) | 2001-02-28 | — | — | EP | claimed |
| WO-1999059573-A9 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2000-05-04 | — | — | WO | claimed |
| WO-1999059573-A1 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER-LAMBERT COMPANY (US) | 1999-11-25 | — | — | WO | claimed |
| US-12383522-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | AMNEAL PHARMACEUTICALS LLC (US) | 2025-08-12 | — | — | US | disclosed |
| US-11931328-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | AMNEAL PHARMACEUTICALS LLC (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240082193-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | AMNEAL PHARMACEUTICALS LLC (US) | 2024-03-14 | — | — | US | disclosed |
| US-11850225-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | AMNEAL PHARMACEUTICALS LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230218554-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | AMNEAL PHARMACEUTICALS LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-11654124-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | AMNEAL PHARMACEUTICALS LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-10792262-B1 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | SAOL INTERNATIONAL LIMITED (BM) | 2020-10-06 | — | — | US | disclosed |
| US-10751312-B1 | — | — | 2020-08-25 | — | — | US | disclosed |
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | disclosed |
| CN-1303991-C | Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivative process for preparing the same | WARNER LAMBERT CO (US) | 2007-03-14 | — | — | CN | disclosed |
| EP-1077692-B1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2004-07-28 | — | — | EP | disclosed |
| CN-1301155-A | Stable pharmaceutical formulation of gamma-aminobutyric acid derivatives and process for preparing the same | WARNER LAMBERT CO (US) | 2001-06-27 | — | — | CN | disclosed |
| WO-1999059573-A9 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10792262-B1 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | ABAT, GABRA6, BCAT2 | ALDH1A1 747/4885ACE 981/4885MME 2292/4885 |
| US-11654124-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | GABRA6, GABBR1, GABBR2 | ALDH1A1 250/4885ACE 1561/4885MME 2974/4885 |
| US-20240082193-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | GABRB1, GABRB2, GABBR1 | ALDH1A1 401/4885ACE 3229/4885MME 1824/4885 |
| US-12383522-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | GABRB1, GABRB2, GABBR1 | ALDH1A1 401/4885ACE 3229/4885MME 1824/4885 |
| US-11931328-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | GABRA6, GABBR1, GABBR2 | ALDH1A1 250/4885ACE 1561/4885MME 2974/4885 |
| US-11850225-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | GABRB1, GABRB2, GABBR1 | ALDH1A1 389/4885ACE 3141/4885MME 1935/4885 |
| US-20230218554-A1 | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | GABRA6, GABBR1, GABBR2 | ALDH1A1 250/4885ACE 1561/4885MME 2974/4885 |
| US-10751312-B1 | — | LIPA, CEL, GANC | ALDH1A1 1231/4885ACE 343/4885MME 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.